Paper36938364
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition.
Thuru X and 3 others. Biomed Hub, 2023. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition. Papers, record 36938364. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36938364
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34103659 | PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. | Commun Biol | 2021 | https://conductscience.org/library/papers/34103659 | PubMed |
| 2 | 27083005 | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). | Oncotarget | 2016 | https://conductscience.org/library/papers/27083005 | PubMed |
| 3 | 32352272 | mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). | ACS Chem Biol | 2020 | https://conductscience.org/library/papers/32352272 | PubMed |
| 4 | 34769226 | PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769226 | PubMed |
| 5 | 32871472 | N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study. | Comput Biol Chem | 2020 | https://conductscience.org/library/papers/32871472 | PubMed |
| 6 | 35132224 | Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/35132224 | PubMed |
| 7 | 31586036 | Crlz-1 Controls Germinal Center Reaction by Relaying a Wnt Signal to the Bcl-6 Expression in Centroblasts during Humoral Immune Responses. | J Immunol | 2019 | https://conductscience.org/library/papers/31586036 | PubMed |
| 8 | 35629327 | Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. | Life (Basel) | 2022 | https://conductscience.org/library/papers/35629327 | PubMed |
| 9 | 27294323 | Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation. | Nat Chem Biol | 2016 | https://conductscience.org/library/papers/27294323 | PubMed |
| 10 | 34381360 | Potential Role of Traditional Chinese Medicines by Wnt/β-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34381360 | PubMed |
| 11 | 30459318 | A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. | Exp Mol Med | 2018 | https://conductscience.org/library/papers/30459318 | PubMed |
| 12 | 31972166 | Protein homodimer sequestration with small molecules: Focus on PD-L1. | Biochem Pharmacol | 2020 | https://conductscience.org/library/papers/31972166 | PubMed |
| 13 | 31839668 | Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. | Biomed Res | 2019 | https://conductscience.org/library/papers/31839668 | PubMed |
| 14 | 35684392 | Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. | Molecules | 2022 | https://conductscience.org/library/papers/35684392 | PubMed |
| 15 | 27470214 | Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer. | BMB Rep | 2016 | https://conductscience.org/library/papers/27470214 | PubMed |
| 16 | 28768162 | Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. | Structure | 2017 | https://conductscience.org/library/papers/28768162 | PubMed |
| 17 | 35630791 | Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents. | Molecules | 2022 | https://conductscience.org/library/papers/35630791 | PubMed |
| 18 | 35352805 | Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives. | Biosci Rep | 2022 | https://conductscience.org/library/papers/35352805 | PubMed |
| 19 | 30965636 | A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30965636 | PubMed |
| 20 | 32445869 | Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer. | Biochem Pharmacol | 2020 | https://conductscience.org/library/papers/32445869 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40206274 | Unraveling the Role of the Wnt Pathway in Hepatocellular Carcinoma: From Molecular Mechanisms to Therapeutic Implications. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/40206274 | PubMed |
| 39038454 | RNA therapeutics targeting PD-L1 is a promising immune-activation strategy against difficult-to-treat cancers. | Mol Ther | 2024 | https://conductscience.org/library/papers/39038454 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| GSK3B | 2932 | PubTator's text mining | https://conductscience.org/library/genes/2932 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| PLP1 | 5354 | PubTator's text mining | https://conductscience.org/library/genes/5354 | NCBI Gene |
| PTPN11 | 5781 | PubTator's text mining | https://conductscience.org/library/genes/5781 | NCBI Gene |
| SPATA2 | 9825 | PubTator's text mining | https://conductscience.org/library/genes/9825 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36938364
GET https://conductscience.org/api/papers/v1/36938364/references?page=2